10.08.2016 • NewsElaine BurridgeconstructionKBR

KBR Wins Chemours Refrigerants Project

Engineering and construction company KBR has been awarded a contract by DuPont spin-off Chemours for a refrigerants project in Corpus Christi, Texas, USA. KBR will provide complete construction services including management and direct hire of labor. The value of the contract was not revealed. Chemours is spending $230 million on the facility, which will produce its hydrofluoroolefin (HFO) 1234yf, known as Opteon YF, a new refrigerant claimed to have extremely low global warming potential. Construction is expected to be completed over a period of 18 months, with start-up expected in the third quarter of 2018.

Early conceptual engineering has already completed; project estimates and detailed design and procurement services are currently being provided by KBR under a long-standing Master Services Agreement. Stuart Bradie, KBR’s president and CEO, said the award showcases the contractor’s integrated engineering, procurement and construction offering, from front-end loading, continuing with detailed design and now including full construction services for the entire project. He added that the company would continue to grow and maintain a substantial presence in the US Gulf Coast region.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read